-
公开(公告)号:US12226491B2
公开(公告)日:2025-02-18
申请号:US17232751
申请日:2021-04-16
Applicant: The Regents of the University of Michigan
Inventor: Duxin Sun , Ryan Clauson , Hongwei Chen , Chengyi Li , Wei Gao , Luke Bugada , Fei Wen , Brett Hill , Syed Monem Rizvi
IPC: A61K47/69 , A61K9/16 , A61K38/19 , A61K39/00 , A61K39/295 , A61K39/39 , A61K45/06 , A61K47/02 , A61K47/64 , A61P35/00
Abstract: The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles. In some embodiments, administration of the nanosatellite complexes to a subject with cancer achieves long-term cancer remission (e.g., when combined with an immune checkpoint inhibitor, such as αPD1).
-
公开(公告)号:US20210346478A1
公开(公告)日:2021-11-11
申请号:US17232751
申请日:2021-04-16
Applicant: The Regents of the University of Michigan
Inventor: Duxin Sun , Ryan Clauson , Hongwei Chen , Chengyi Li , Wei Gao , Luke Bugada , Fei Wen , Brett Hill , Syed Monem Rizvi
IPC: A61K39/00 , A61K47/02 , A61K9/16 , A61K38/19 , A61K47/69 , A61K47/64 , A61K45/06 , A61K39/295 , A61P35/00 , A61K39/39
Abstract: The present invention provides, in some embodiments, methods, compositions, systems, and kits comprising nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; 3-25 satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and at least one additional property. In other embodiments, provided herein are nano-satellite complexes comprising: a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; a plurality of satellite particles attached to, or absorbed to, said biocompatible coating; a plurality of antigenic peptides conjugated to, or absorbed to, said satellite particles; and a plurality of LIGHT (TNFSF14) peptides conjugated to, or absorbed to, said satellite particles. In some embodiments, administration of the nanosatellite complexes to a subject with cancer achieves long-term cancer remission (e.g., when combined with an immune checkpoint inhibitor, such as αPD1).
-
公开(公告)号:US20240226104A1
公开(公告)日:2024-07-11
申请号:US18556250
申请日:2022-04-20
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor: Wei Gao , Duxin Sun , Fei Wen , Ruiting Li , Hongxiang Hu , Luke F. Bugada , Yudong Song , Mahamadou Djibo
IPC: A61K31/519 , A61K9/00 , A61K9/51 , A61K31/337 , A61P35/04
CPC classification number: A61K31/519 , A61K9/0019 , A61K9/5169 , A61K31/337 , A61P35/04
Abstract: The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors, and compositions, nanoformulations and methods for treating diseases or disorders (e.g., breast cancer, pancreatic cancer, lung cancer, and lymphoma) with PBK inhibitors or composition thereof. Disclosed herein is a composition comprising: an effective amount of a PI3K inhibitor or a pharmaceutically acceptable salt thereof; and an albumin nanoparticle.
-
公开(公告)号:US11819516B2
公开(公告)日:2023-11-21
申请号:US15773952
申请日:2016-11-04
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor: Fei Wen , Mason Smith
IPC: C12N15/62 , C12N5/0783 , C07K14/39 , A61K35/17 , A61K48/00 , A61K47/61 , A61K47/68 , A61K38/17 , C07K19/00
CPC classification number: A61K35/17 , A61K38/1774 , A61K47/61 , A61K47/6889 , A61K48/00 , C07K14/39 , C07K19/00 , C12N5/0636 , C12N15/62 , C07K2318/10 , C07K2319/02 , C07K2319/035
Abstract: Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells using a peptide-major histocompatibility complex (pMHC) assembled on a protein scaffold for patterned signal presentation of T cell activating ligands to T cells.
-
公开(公告)号:US11020470B2
公开(公告)日:2021-06-01
申请号:US15566069
申请日:2016-04-12
Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventor: Fei Wen , Eshita Khera , Brett Dallas Hill , Syed Rizvi
IPC: A61K39/12 , C12N15/81 , A61K39/145 , A61K39/21 , C07K14/395 , A61K39/00
Abstract: Provided herein are membrane enveloped virus-like particles (VLPs), and methods of use and synthesis thereof. In particular, yeast-cell-derived VLPs are provided that comprise surface-displayed glycoproteins and/or multiple virally-derived proteins.
-
-
-
-